Abivax (AAVXF) Notes Payables (2021 - 2025)

Abivax has reported Notes Payables for 4 years, with the latest figure at $4.1 million in Q2 2025.

• On a quarterly basis, Notes Payables rose 79.08% year-over-year to $4.1 million in Q2 2025; TTM through Jun 2025 was $4.1 million, a 79.08% increase from a year earlier, with the FY2024 full-year figure at $3.9 million, changed N/A from the prior year.
• Notes Payables was $4.1 million for Q2 2025 at Abivax, up from $4.0 million in the prior quarter.
• The five-year high for Notes Payables was $11.4 million in Q4 2021, with the low at $577460.0 in Q4 2022.
• Average Notes Payables over 4 years is $4.4 million, with a median of $3.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Notes Payables tumbled 94.92% in 2022, then surged 79.08% in 2025.
• Over 4 years, Notes Payables stood at $11.4 million in 2021, then sank by 94.92% to $577460.0 in 2022, then surged by 569.88% to $3.9 million in 2024, then grew by 6.49% to $4.1 million in 2025.
• The last three Notes Payables figures came in at $4.1 million (Q2 2025), $4.0 million (Q1 2025), and $3.9 million (Q4 2024), per Business Quant data.